In a groundbreaking study published in Nature Neuroscience on March 18, 2026, researchers at MIT have unveiled new insights into the neurological underpinnings of schizophrenia, specifically highlighting the critical role of mediodorsal thalamus neurons and a genetic mutation in the gene grin2a. This discovery brings a new dimension to understanding the cognitive impairments frequently observed in schizophrenia, particularly difficulties in updating beliefs and decision-making when confronted with new information.
Schizophrenia, a complex psychiatric disorder with profound cognitive and behavioral symptoms, affects approximately 1% of the global population. A significant barrier to effective treatment has been the incomplete understanding of how genetic and neural circuit alterations contribute to cognitive deficits, such as disordered thinking and impaired sensory integration. The team at MIT, led by Guoping Feng, focused on elucidating the mechanisms behind impaired belief updating—a cognitive hallmark hypothesized to underlie psychosis—using a sophisticated genetic mouse model.
The study centers on a mutation in the grin2a gene, which encodes a subunit of the NMDA receptor, an essential glutamate receptor integral to synaptic plasticity and neuronal communication. Previous large-scale genomic screenings identified grin2a as one of the top genes harboring mutations with a strong association to schizophrenia. Given the gene’s role in synaptic signaling, the researchers posited that alterations in grin2a could disrupt neural circuits crucial for cognitive flexibility and updating beliefs based on sensory input.
To investigate this, the researchers engineered mice carrying the grin2a mutation and subjected them to behavioral paradigms designed to probe cognitive adaptation to changing reward contingencies. In one key experiment, mice were trained to choose between two levers: one that offered a higher reward but required more effort, and another providing a smaller reward at less cost. Wild-type mice adapted their choices as the task parameters evolved, shifting preference from the high-effort lever to the low-effort one when it became more advantageous. Contrastingly, mutant mice exhibited prolonged indecision and a delayed switch in preference, indicative of impaired belief updating and reduced cognitive flexibility.
Delving deeper into the neural dynamics, the team employed functional ultrasound imaging alongside electrophysiological recordings to pinpoint disruptions within the mediodorsal thalamus, a crucial hub interfacing with the prefrontal cortex to regulate executive functions and decision-making processes. In mice carrying the grin2a mutation, neuronal activity in this thalamic region was diminished and exhibited aberrant patterns correlating with their maladaptive decision behaviors. This supports the theory that dysfunctional thalamocortical circuits impair the integration of new sensory evidence into existing cognitive frameworks.
Taking a step further, the scientists utilized optogenetics to selectively stimulate mediodorsal thalamus neurons in mutant mice, effectively rescuing the deficits in adaptive behavior. By activating these neurons with precisely timed light pulses, the mice began to demonstrate decision-making patterns more akin to their wild-type counterparts. This pioneering intervention highlights the therapeutic potential of targeting discrete neural circuits to ameliorate specific cognitive symptoms of schizophrenia.
The implications of this study extend beyond the grin2a mutation itself. Although only a minority of schizophrenia patients carry mutations in this gene, the identified thalamocortical circuit deficits may represent a convergent pathway through which disparate genetic abnormalities manifest similar cognitive impairments. This circuit-based perspective advocates for a shift in therapeutic strategies from focusing solely on individual genes to modulating neural network function.
Moreover, this research provides a mechanistic explanation for psychosis-related belief disturbances long hypothesized in psychiatric literature. The concept that patients with schizophrenia overweigh prior beliefs at the expense of new sensory information is now traceable to concrete neurogenetic and circuit-level dysfunctions, bridging the gap between high-level cognitive theories and molecular neuroscience.
The study was made possible by a multidisciplinary approach combining behavioral neuroscience, advanced imaging, genetic engineering, and optogenetic technology. This integrative methodology sets a new standard for modeling complex psychiatric disorders and exploring potential interventions in preclinical settings.
Funding support from institutions including the National Institutes of Mental Health and the Stanley Center for Psychiatric Research underscored the importance and collaborative nature of this work. As the researchers continue to dissect the components of this thalamocortical circuit, they aim to identify druggable targets that could restore circuit function and improve cognitive outcomes for patients living with schizophrenia.
Ultimately, this research paves the way for novel treatments that go beyond symptomatic relief toward addressing the neural dysfunctions that underlie the debilitating cognitive and perceptual disturbances of schizophrenia. It marks a significant step forward in psychiatry’s quest to unravel the complex biology of mental illness and develop precision medicine approaches tailored to individual neural circuitry deficits.
Subject of Research: Animals
Article Title: Reduced mediodorsal thalamus activity underlies aberrant belief dynamics in a genetic mouse model of schizophrenia
News Publication Date: 18-Mar-2026
Web References: http://dx.doi.org/10.1038/s41593-026-02237-9
Image Credits: MIT
Keywords: Neuroscience, Psychiatric disorders, Schizophrenia, Brain, Human brain, Genetics, Cognitive impairment, Mediodorsal thalamus, NMDA receptor, grin2a gene, Optogenetics, Thalamocortical circuit
